Share on StockTwits
 

Covidien PLC (NYSE:COV)’s share price reached a new 52-week high during trading on Thursday, ARN reports. The stock traded as high as $69.09 and last traded at $69.09, with a volume of 1,142,091 shares traded. The stock had previously closed at $68.25.

Several analysts have recently commented on the stock. Analysts at JMP Securities initiated coverage on shares of Covidien PLC in a research note to investors on Friday, December 13th. They set an “outperform” rating and a $76.00 price target on the stock. Separately, analysts at Barclays raised their price target on shares of Covidien PLC from $72.00 to $77.00 in a research note to investors on Thursday, December 5th. They now have an “overweight” rating on the stock. Finally, analysts at Benchmark Co. initiated coverage on shares of Covidien PLC in a research note to investors on Thursday, December 5th. They set a “buy” rating and a $82.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $72.88.

Covidien PLC has a 52-week low of $52.6418 and a 52-week high of $68.88. The stock has a 50-day moving average of $67.30 and a 200-day moving average of $62.92. The company has a market cap of $31.356 billion and a price-to-earnings ratio of 18.90.

Covidien PLC (NYSE:COV) last posted its quarterly earnings results on Friday, November 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.01. The company had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.56 billion. During the same quarter in the previous year, the company posted $1.02 earnings per share. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. Analysts expect that Covidien PLC will post $3.99 EPS for the current fiscal year.

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.